“The Chronic Hepatitis B market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Chronic Hepatitis B pipeline products will significantly revolutionize the Chronic Hepatitis B market dynamics”

 

The Chronic Hepatitis B market report provides current treatment practices, Chronic Hepatitis B emerging drugs, market share of individual therapies, and current and forecasted 7MM a Chronic Hepatitis B market size from 2019 to 2032. The report also covers current Chronic Hepatitis B treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Chronic Hepatitis B Market Research Report

• According to DelveInsight estimates, there were around 3,04,900 and 53,800 cases of compensated and decompensated liver in Japan in 2022. These cases are projected to increase during the forecast period.
• In the United States, approximately 55% of the patient share is attributed to males, whereas around 40% of females suffer from Chronic Hepatitis B.
• The leading companies working in the Chronic Hepatitis B Market include Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis, and others.
• Promising Chronic Hepatitis B Pipeline Therapies in the various stages of development include Tenofovir Alafenamidem, VIR-221, Selgantolimod,  telbivudine, lamivudine, pegylated interferon-alfa 2a, and others.
• September 2023: Brii Biosciences Limited announced a study of phase 2 clinical trials for PEG-IFNα and BRII-835. This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
• September 2023: Gilead Sciences announced a study of phase 1 clinical trials for GS-2829 and GS-6779. The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.

 

Discover more about therapies set to grab major Chronic Hepatitis B Market Share @ Chronic Hepatitis B Market Size

 

Chronic Hepatitis B Overview

Chronic Hepatitis B (CHB) has been described as “a heterogeneous disease with markedly variable levels of viral replication and liver disease activity”. It is characterized by liver injury mediated by a T-cell immune response targeting hepatocytes that express viral antigens.

 

Chronic Hepatitis B Epidemiology Segmentation in the 7MM

• Total Chronic Hepatitis B Prevalent Cases
• Total Chronic Hepatitis B Diagnosed Prevalent Cases
• Chronic Hepatitis B Gender-specific Diagnosed Prevalent Cases
• Chronic Hepatitis B Age-specific Diagnosed Prevalent Cases
• Chronic Hepatitis B Type-specific Diagnosed Prevalent Cases
• Total Chronic Hepatitis B Treated Cases

 

Download the report to understand which factors are driving Chronic Hepatitis B Epidemiology Trends @ Chronic Hepatitis B Epidemiological Insights

 

Chronic Hepatitis B Marketed Drugs

 

• VEMLIDY (tenofovir alafenamide): Gilead Sciences

VEMLIDY is an HBV nucleoside analog reverse transcriptase inhibitor. It is approved for treating Chronic Hepatitis B infection in adults and pediatric patients 12 years and older with compensated liver disease. Recently, VEMLIDY received approval for pediatric patients 12 years and older with Chronic Hepatitis B infection with compensated liver disease in November 2022 in the United States. However, the drug was first approved in the United States and Japan, followed by approvals in the EU (2017) for adult patients with Chronic Hepatitis B.

 

Chronic Hepatitis B Emerging Drugs

 

• Bepirovirsen (GSK3228836): GlaxoSmithKline/Ionis Pharma

Bepirovirsen (GSK3228836) is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) that facilitate chronicity of the disease by helping avoid clearance by the immune system. The assets were in-licensed by GSK from Ionis Pharmaceuticals in August 2019.

 

To know more about Chronic Hepatitis B Treatment options, visit @ Chronic Hepatitis B Drugs

 

Chronic Hepatitis B Drugs Market

The existing Chronic Hepatitis B treatment is mainly dominated by antiviral drugs such as entecavir, VEMLIDY, VIREAD, telbivudine, adefovir dipivoxil, and lamivudine. Lamivudine was the first NA to be given the go-ahead by US FDA for treating Chronic hepatitis B. The drug was given adult approval in 1998, while pediatric approval for children aged 2–17 was given in 2001. But since 1995, this drug has been used and licensed for treating HIV infection. With few side effects, it can be used successfully in various patients. However, lamivudine therapy for a prolonged time is linked to significant rates of drug resistance, which cause virological relapse and biochemical flare. Lamivudine is suggested as a second-line therapy for managing Hepatitis B.

 

Chronic Hepatitis B Market Outlook

Chronic Hepatitis B treatment in the US is entering a new era with changing dynamics. To this date, several drugs have been approved by the US FDA to treat Chronic Hepatitis B: interferon-alpha and pegylated interferon-alpha, nucleoside analogs (NA), and nucleotide analog prodrugs. Oral antiviral medications include VIREAD (tenofovir disoproxil), VEMLIDY (tenofovir alafenamide), BARACLUDE (entecavir), TYZEKA or SEBIVO (telbivudine), HEPSERA (adefovir dipivoxil), and lamivudine (Epivir-HBV, Zeffix, or Heptodin). The aforementioned therapies help fight the virus and slow its ability to damage the liver.

 

Learn more about the Chronic Hepatitis B Pipeline Therapies in clinical trials @ Chronic Hepatitis B Market Landscape

 

Scope of the Chronic Hepatitis B Market Report

• Coverage-7MM
• Study Period- 2019-2032
• Chronic Hepatitis B Companies- Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis, and others.
• Chronic Hepatitis B Pipeline Therapies- Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a, and others.
• Chronic Hepatitis B Market Dynamics: Ataxia Telangiectasia Market Drivers and Barriers
• Chronic Hepatitis B Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Chronic Hepatitis B Drugs in development @ Chronic Hepatitis B Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Hepatitis B Market Overview at a Glance

4. Executive Summary of Chronic Hepatitis B

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Hepatitis B Infection

8. Current Treatment Practices

9. Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Chronic Hepatitis B Clinical Trials

12. Marketed Therapies

13. Emerging Therapies

14. Discontinued Drugs

15. Chronic Hepatitis B: The 7MM Analysis

16. Market Access and Reimbursement

17. KOL Views

18. SWOT Analysis

19. Unmet Needs

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking